{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:59:46Z","timestamp":1772747986847,"version":"3.50.1"},"reference-count":29,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Phathom Pharmaceuticals","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2022,7,7]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Management of erosive oesophagitis (EE) remains suboptimal, with many patients experiencing incomplete healing, ongoing symptoms, and relapse despite proton pump inhibitor (PPI) treatment. The Study of Acid-Related Disorders investigated patient burden of individuals with EE in a real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>US gastroenterologists (GIs) or family physicians (FPs)\/general practitioners (GPs) treating patients with EE completed a physician survey and enrolled up to four patients with EE for a patient survey, with prespecified data extracted from medical records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>102 GIs and 149 FPs\/GPs completed the survey; data were available for 73 patients (mean age at diagnosis, 45.4 years). Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60.8% GIs; 56.4% FPs\/GPs), and pantoprazole preferred second line (29.4% and 32.9%, respectively). Price and insurance coverage (both 55.5% HCPs) and familiarity (47.9%) key drivers for omeprazole; insurance coverage (52.0%), price (50.0%), familiarity (48.0%), initial symptom relief (46.0%), and safety (44.0%) key drivers for pantoprazole. Only 49.3% patients took medication as instructed all the time; 56.8% independently increased medication frequency some of the time. Despite treatment, 57.5% patients experienced heartburn and 30.1% regurgitation; heartburn was the most bothersome symptom. 58.9% patients believed that their symptoms could be better controlled; only 28.3% HCPs were very satisfied with current treatment options. 83.6% patients wanted long-lasting treatment options. Fast symptom relief for patients was a top priority for 66.1% HCPs, while 56.6% would welcome alternatives to PPIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This real-world multicentre study highlights the need for new, rapidly acting treatments in EE that reduce symptom burden, offer durable healing and provide symptom control.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2022-000941","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T11:26:32Z","timestamp":1658489192000},"page":"e000941","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients"],"prefix":"10.1136","volume":"9","author":[{"given":"Michael F","family":"Vaezi","sequence":"first","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Brunton","sequence":"additional","affiliation":[{"name":"Primary Care Education Consortium, Winnsboro, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mark Fendrick","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Department of Internal Medicine, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin W","family":"Howden","sequence":"additional","affiliation":[{"name":"University of Tennessee, Tennessee, Nashville, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9417-695X","authenticated-orcid":false,"given":"Christian","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, Cheshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Phathom Pharmaceuticals, New Jersey, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinu","family":"Jacob","sequence":"additional","affiliation":[{"name":"Phathom Pharmaceuticals, New Jersey, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J","family":"Spechler","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Baylor University Medical Center at Dallas, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"2025073013470460000_9.1.e000941.1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304269"},{"key":"2025073013470460000_9.1.e000941.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.07.045"},{"key":"2025073013470460000_9.1.e000941.3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2025073013470460000_9.1.e000941.4","unstructured":"Antunes C , Aleem A , Curtis SA . Gastroesophageal Reflux Disease. In: StatPearls. 2022, StatPearls Publishing Copyright \u00a9 2022. StatPearls Publishing LLC.: Treasure Island (FL)."},{"key":"2025073013470460000_9.1.e000941.5","doi-asserted-by":"publisher","DOI":"10.1111\/dote.12495"},{"key":"2025073013470460000_9.1.e000941.6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5056\/jnm15105","article-title":"Unmet needs in the treatment of gastroesophageal reflux disease","volume":"21","author":"Dickman","year":"2015","journal-title":"J Neurogastroenterol Motil"},{"key":"2025073013470460000_9.1.e000941.7","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.326"},{"key":"2025073013470460000_9.1.e000941.8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000854","article-title":"World gastroenterology organisation global guidelines: GERD global perspective on gastroesophageal reflux disease","volume":"51","author":"Hunt","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"2025073013470460000_9.1.e000941.9","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.444"},{"key":"2025073013470460000_9.1.e000941.10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314722"},{"key":"2025073013470460000_9.1.e000941.11","doi-asserted-by":"publisher","DOI":"10.1159\/000094789"},{"key":"2025073013470460000_9.1.e000941.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02643.x"},{"key":"2025073013470460000_9.1.e000941.13","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9178669"},{"key":"2025073013470460000_9.1.e000941.14","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199802000-00004"},{"key":"2025073013470460000_9.1.e000941.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00354-9"},{"key":"2025073013470460000_9.1.e000941.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04774.x"},{"key":"2025073013470460000_9.1.e000941.17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000143796","article-title":"Maintenance treatment for GERD: residual symptoms are associated with psychological distress","volume":"77","author":"van der Velden","year":"2008","journal-title":"Digestion"},{"key":"2025073013470460000_9.1.e000941.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00288-5"},{"key":"2025073013470460000_9.1.e000941.19","unstructured":"Prevention CfDCa . Health insurance portability and accountability act of 1996 (HIPAA), 2021. Available: https:\/\/www.cdc.gov\/phlp\/publications\/topic\/hipaa.html [Accessed 20 June 2022]."},{"key":"2025073013470460000_9.1.e000941.20","unstructured":"Association, E.P.M.R . Code of conduct, 2021. Available: https:\/\/www.ephmra.org\/media\/5214\/2021-ephmra-code-of-conduct-21121.pdf [Accessed 20 June 2022]."},{"key":"2025073013470460000_9.1.e000941.21","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14075","article-title":"ESNM\/ANMS consensus paper: diagnosis and management of refractory gastro-esophageal reflux disease","volume":"33","author":"Zerbib","year":"2021","journal-title":"Neurogastroenterol Motil"},{"key":"2025073013470460000_9.1.e000941.22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000497775","article-title":"Efficacy of Vonoprazan, a novel potassium-competitive acid blocker, in patients with proton pump Inhibitor-Refractory acid reflux","volume":"101","author":"Akiyama","year":"2020","journal-title":"Digestion"},{"key":"2025073013470460000_9.1.e000941.23","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17745776","article-title":"Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date","volume":"11","author":"Sugano","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"2025073013470460000_9.1.e000941.24","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/apt.16959","article-title":"The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study","volume":"55","author":"Chen","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013470460000_9.1.e000941.25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1358\/dot.2020.56.11.3202811","article-title":"Tegoprazan to treat gastroesophageal reflux disease","volume":"56","author":"Mermelstein","year":"2020","journal-title":"Drugs Today"},{"key":"2025073013470460000_9.1.e000941.26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm18139","article-title":"Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker","volume":"25","author":"Mori","year":"2019","journal-title":"J Neurogastroenterol Motil"},{"key":"2025073013470460000_9.1.e000941.27","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/apt.16930","article-title":"Review article: rethinking the \"ladder\" approach to reflux-like symptom management in the era of PPI \"resistance\" - a multidisciplinary perspective","volume":"55","author":"Hungin","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013470460000_9.1.e000941.28","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","article-title":"AGA clinical practice update on De-Prescribing of proton pump inhibitors: expert review","volume":"162","author":"Targownik","year":"2022","journal-title":"Gastroenterology"},{"key":"2025073013470460000_9.1.e000941.29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ajg.2012.447","article-title":"Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy","volume":"108","author":"Shaheen","year":"2013","journal-title":"Am J Gastroenterol"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2022-000941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:47:16Z","timestamp":1753908436000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2022-000941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,7,22]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bmjgast-2022-000941"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2022-000941","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}